Beyes Introduces the Masteri Class B Automatic Cycle Autoclave


Thanks to Precision Engineering and Rigorous Clinical Testing,
The Masteri Meets and Exceeds Class B+N Autoclave Standards
Toronto, CAN – June 26, 2018 –   Beyes Dental Canada recently launched the highly-advanced Masteri Class B automatic cycle autoclave unit. The Masteri Class B Autoclave also has the following distinctive main attributes:
·       Speedy – Thoroughly sterilized instruments are available in 21 minutes.
·       Safe – Meets all the latest safety and regulatory requirements. The Masteri includes a hook-type door lock, a micro-switch door locking system and an electronic door lock.
·       Secure – Built-in data logger stores your information on a USB drive that is waterproof and shockproof with an internal printer available as an option.
·       Simple – A full range of sterilization options can be easily selected via an intuitive touch display.
The Masteri is available in 18 and 23-liter chamber sizes and is built to withstand the toughest environments and high-volume demands. It also incorporates a pre-vac mode which removes air from the chamber to ensure optimal steam penetration, as well as a post-vac mode for removing air from the chamber for ultra-fast drying.
The Masteri is also the first autoclave with capacitive sensing control which can detect and measure anything that is conductive or has a dielectric that is different than the surrounding air. Because of this, the touch pad is seamless, and the buttons are fully-protected from dirt and moisture and can be activated while wearing exam gloves.
According to company spokesperson, Jannis Tu, “We’re very proud of the newest member of the Beyes product family. The Masteri is the result of a stringent process of research, design, prototyping and clinical testing. The final product is one of the most reliable, high-performance autoclave units currently on the market –  and the only one that comes with a 25-month warranty.”
For more information on the Masteri Class B Auto Cycle Autoclave, visit http://bit.ly/2N1fkKq
or send an email to info@Beyes.ca.
About Beyes Canada
Based in Toronto, Beyes is Canada’s fastest-growing dental company, thanks to its loyal customers. Beyes combines the expertise of highly-skilled people with its well-established manufacturing chain and advanced quality-control systems to provide the dental community with groundbreaking advancements for precision dental instruments.
All Beyes products are manufactured in strict compliance with Health Canada regulations. Moreover, the manufacturing facility is ISO 13485 certified under Canadian Medical Devices Conformity Assessment System (CMDCAS) ensuring superior products quality that meet and exceed user expectations.
The Beyes team is dedicated to providing flawless experience to its customers, at all levels assuring that products and service not only meet but exceed current and future demands. For more information, about Beyes Canada, visit www.Beyes.ca.
# # #
Continue reading

The Use of Amoxicillin (500mg) Plus Metronidazole (500mg) For 7 Days Adds Adjunctive Benefits For Non-Surgical Periodontal Therapy, But Limited Evidence Supports Higher/Longer Dose


Summary

Selection Criteria:

The search was conducted through the electronic database of Embase and MEDLINE (via OvidSP) from 1946 to April 2017 for randomized clinical trials on different combinations and modifications of the key words, including periodontitis, amoxicillin, metronidazole, and randomized controlled clinical trial. The Cochrane Central Register and the WHO International Clinical Trials Registry Platform were also searched for relevant clinical trials. The reference lists of all included studies and relevant reviews were manually cross-referenced to ensure comprehensive data collection. Two reviewers conducted the screening, quality assessment, and selection of the articles.

Key Study Factor

The key study factor (intervention) was blinded, randomized placebo-controlled trials with nonsurgical periodontal therapy and adjunctive consumption of amoxicillin and metronidazole. However, there is heterogeneity of the length and dose of the antibiotics prescribed.

Main Outcome Measure

The primary outcomes assessed were periodontal pocket probing depth and clinical attachment level 3 months after a combination of nonsurgical periodontal therapy and use of the systematic antibiotics amoxicillin and metronidazole.

Main Results

Out of the 376 records identified, 18 studies were included for qualitative synthesis and 15 studies included for quantitative analysis. Meta-analysis showed a small beneficial effect of adjunctive amoxicillin plus metronidazole for an additional mean weighted pocket depth reduction of 0.36-0.38 mm. No clinically significant difference was found among the various doses and durations for the medication use.

Conclusions

Based on the studies reviewed, no recommendations for the optimal duration of the antibiotic course can be given. However, based on the principles of responsible antibiotics use, the highest dose with the shortest duration of time is recommended to reduce the risk of antibiotic resistance. Therefore, a 7-day regimen of 500/500 mg or 500/400 mg of amoxicillin and metronidazole would be most appropriate.
Continue reading

Dentists’ prescribing of antibiotics and opioids to Medicare Part D beneficiaries: Medications of high impact to public health.

J Am Dent Assoc. 2018 Jun 18. pii: S0002-8177(18)30310-6. doi: 10.1016/j.adaj.2018.04.027. [Epub ahead of print]

Abstract

BACKGROUND:

Gaining a better understanding of dental prescribing can help identify opportunities for intervention regarding optimal medication use. The purpose of this study is to characterize opioid and antibiotic prescribing patterns of dentists in the United States for Medicare Part D beneficiaries.

METHODS:

The authors conducted a retrospective cross-sectional analysis of national 2014 Medicare Part D Prescriber Public Use File data. Providers in the data set with dental-related disciplines were included (n = 99,797). Outcomes of interest were mean days’ supply and mean number of claims reported per claim, beneficiary, and prescriber discipline.

RESULTS:

Of the 6,724,372 dental prescription claims submitted, 3,947,848 (58.7%) and 1,312,796 (19.5%) were for antibiotics and opioids, respectively. Sixty-nine percent of dentists in the highest quartile of opioid prescribers were also in the highest quartile of antibiotic prescribers (r2 = 0.7778; P < .01). The mean (standard deviation) days’ supply per claim was 6.9 (5.3) days (range, 1-90 days) for antibiotics and 3.6 (2.0) days (range, 1-44.5 days) for opioids. Of the 33,348 dental providers who prescribed opioids, 18,971 (56.9%) prescribed a mean opioid days per claim greater than the recommended duration of 3 days for acute pain.

CONCLUSION:

Opioids and antibiotics are the medications most prescribed by dentists. On the basis of national recommendations and results of studies from other countries, the length of therapy prescribed may be excessive. Further studies should be conducted to assess appropriateness of dental prescriptions.

PRACTICAL IMPLICATIONS:

Dentistry should be considered for antibiotic and opioid stewardship interventions along with medicine.

Continue reading